Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.27 USD
Change Today -0.16 / -3.61%
Volume 192.0K
BCLI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ CM
As of 5:20 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

brainstorm cell therapeutics (BCLI) Snapshot

Open
$4.34
Previous Close
$4.43
Day High
$4.40
Day Low
$4.21
52 Week High
01/2/15 - $8.47
52 Week Low
12/12/14 - $2.81
Market Cap
78.5M
Average Volume 10 Days
174.8K
EPS TTM
$-0.56
Shares Outstanding
18.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BRAINSTORM CELL THERAPEUTICS (BCLI)

brainstorm cell therapeutics (BCLI) Related Bloomberg News

View More Bloomberg News

brainstorm cell therapeutics (BCLI) Related Businessweek News

No Related Businessweek News Found

brainstorm cell therapeutics (BCLI) Details

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is based in New York, New York.

15 Employees
Last Reported Date: 11/13/14
Founded in 2000

brainstorm cell therapeutics (BCLI) Top Compensated Officers

President
Total Annual Compensation: --
Chief Financial Officer and Principal Account...
Total Annual Compensation: $106.0K
Compensation as of Fiscal Year 2013.

brainstorm cell therapeutics (BCLI) Key Developments

Brainstorm Cell Therapeutics Inc. to Report Q4, 2014 Results on Mar 26, 2015

Brainstorm Cell Therapeutics Inc. announced that they will report Q4, 2014 results at 9:00 AM, Eastern Standard Time on Mar 26, 2015

Brainstorm Cell Therapeutics Inc., Q4 2014 Earnings Call, Mar 26, 2015

Brainstorm Cell Therapeutics Inc., Q4 2014 Earnings Call, Mar 26, 2015

Brainstorm Cell Therapeutics Inc. Receives Notice of Allowance for its Nurown Technology Platform from Israel's Patent Office

BrainStorm Cell Therapeutics Inc. announced that it has received a Notice of Allowance from Israel's Patent Office for its patent application titled 'Isolated Population of Cells, Methods of Generating Same, and Uses Thereof in the Treatment of CNS Diseases'. This patent is held jointly with Ramot, Tel Aviv University's technology transfer company. This patent claims neurotrophic factor-secreting cells derived from mesenchymal stem cells, methods for producing those cells, and methods of using those cells for the treatment of neurologic diseases.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCLI:US $4.27 USD -0.16

BCLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BCLI.
View Industry Companies
 

Industry Analysis

BCLI

Industry Average

Valuation BCLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRAINSTORM CELL THERAPEUTICS, please visit www.brainstorm-cell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.